ARCHIVES

FDA Approval of Abraxane Sets Stage for Competition Between Taxane Drugs. Abraxane a Nanotechnology Drug? Sponsor Says Yes, FDA Says.

This article is from The Cancer Letter archive.

Vol. 31 No. 02 | January 14, 2005

Download PDF Visit The Full Archive

Related Articles

House DoD Report Provides $15 Million For Lung Cancer Screening

October 23, 2009

To nurture staff, NCI plans an academy.

February 13, 2004

ASCO, Pathologists Publish Guideline On Improving Accuracy Of HER2 Testing

December 29, 2006

NEJM Sanctioned For Giving CME Credit For Controversial Lung Screening Paper; ACCME Demanded Corrective Action

January 9, 2009

Group Lobby To Add $200 Mil. To Cancer Budget

April 26, 1991

Tracor Lands Second Biggest NCI Contract-$6.6 Million To Manage Commercial Labs’ Portion Of Bioassay Program

April 19, 1974